Psychiatr. pro Praxi, 2004; 5: 276-280

Amisulprid - mýty a fakta

doc. MUDr. Vladimír Pidrman Ph.D, MUDr. Klára Látalová
Psychiatrická klinika FN a LF UP, Olomouc

Keywords: amisulprid, negativní symptomatologie, pozitivní symptomatologie, hmotnost, hyperprolaktinémie, olanzapin.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Látalová K. Amisulprid - mýty a fakta. Psychiatr. praxi. 2004;9(5):276-280.

Autoři uvádějí přehled účinnosti amisulpridu v kontextu s dalšími atypickými antipsychotiky. Zaměřili se zejména na otázku účinnosti v léčbě negativní a pozitivní symptomatologie, otázku zvýšení hmotnosti při léčbě schizofrenie, věnují se hyperprolaktinémii a názorům na její případná rizika. Poslední část sdělení je věnována seznámení s recentní šestiměsíční studií srovnávající za kontrolovaných podmínek amisulprid s olanzapinem.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Braunwald E. Harisson´s principles of internal medicine. McGraw-Hill Book Comp., New York, 2001: 3211.
    2. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol., 1999; 14: 1-10. Go to original source... Go to PubMed...
    3. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. J Clin Psychopharmacol 1999; 14: 209-218. Go to original source... Go to PubMed...
    4. Curran M, Perry C. Amisulpride. A review of its use in the management of schizofrenia. Drugs, 2001; 61 (14): 2123-2210. Go to original source... Go to PubMed...
    5. Danion JM, Rein W, Fleurot O, et al. The Amisulpride Study Group: Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am. J. Psychiatry, 1999; 156: 610-616. Go to original source... Go to PubMed...
    6. Davis JM, Chen N, Glick ID. A meta - analysis of the efficacy of second generation antipsychotics. Arch. Gen. Psychiatry, 2003; 60: 553-563. Go to original source... Go to PubMed...
    7. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35: 75-86. Go to original source... Go to PubMed...
    8. Gründer G, Wetzel H, Schlösser R, et al. Neuroendocrine response to antipsychotics: Effects of drug type and gender. Biol Psychiatry 1999; 45: 89-97. Go to original source... Go to PubMed...
    9. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients. Guidelines for avoidance and management. CNS Drugs 1998; 10: 209-222. Go to original source...
    10. Hummer M, Huber J. Hyperprolactinemia and antipsychotic therapy in schizofrenia. Current medical research and opinion, 2004; 20: 2, 189-197. Go to original source... Go to PubMed...
    11. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302: 1129-1134. Go to original source... Go to PubMed...
    12. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57-61. Go to original source... Go to PubMed...
    13. Leucht S, Pitschel-Walz G, Kissling W, Engel RR. A meta-analysis of studies with the atypical antipsychotic amisulpride. In: Dopamine in the pathophysiology and treatment of schizofrenia. Martin Dunitz, London, 2003: 93-109. Go to original source...
    14. Leucht S, Barnes TRE, Kisssling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta analysis of randomized, controlled trials. Am. J. Psychiatry, 2003; 160, 7: 1209-1222. Go to original source... Go to PubMed...
    15. Marek J. Prolaktin a psychofarmakologie. Psychiatrie, 2004; 8 (suppl 2) 8-15.
    16. Martin S, Loo H, Peukens J, Thirumalai S, et al. A double-blind randomised comparative trial of amisulpride vesus olanzapine in the treatment of schizophrenia: Short-term results at two months. Current Medical Research and Opinion, 2002; 18, 6: 355-362. Go to original source... Go to PubMed...
    17. Mortimer A, Martin S, Loo H, Peuskers J. A double-blind randomised comparative trial of amisulpride vesus olanzapine for 6 months in the treatment of schizophrenia.Int., Clin. Psychopharmacology, 2004; 19, 2: 63-69. Go to original source... Go to PubMed...
    18. Novotný J, Petruželka L. Modifikuje psychiatrická medikace riziko vzniku nádorových onemocnění? Psychiatrie, 2004; 8 (suppl 2) 16-19.
    19. Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research, 1999; 88: 107-117. Go to original source... Go to PubMed...
    20. Puetch A, Fleurot O, Rein W, Amisulpride Study Group: Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr. Scand. 1998; 98: 65-72. Go to original source... Go to PubMed...
    21. Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short-and long-term use. Acta Psychiatr. Scand., 2000; 101: 23-27. Go to original source... Go to PubMed...
    22. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs, 2001; 15, 7: 537-551. Go to original source... Go to PubMed...
    23. Sechter D, Peuskers J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophhrenia: Results of a 6-mont double-blind study. Neuropsychopharmacol 2002; 27: 1071-1081. Go to original source... Go to PubMed...
    24. Schlösser R, Gründer G, Anghelescu I, et al. Long-term effects of the substitued benzamide derivate amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002; 46: 33-40. Go to original source... Go to PubMed...
    25. Taylor D, Paton C, Kervin R. 2003 prescribing guidelines. 7-th edition. Martin Dunitz, London, 2003: 272. Go to original source...
    26. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand, 2000; 101: 416-432. Go to original source... Go to PubMed...
    27. Wang PS, Wealker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-1154. Go to original source... Go to PubMed...
    28. Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology. American Psychiatric Publishing, Inc., Washington DC, 2003: 588 s.
    29. Masarykův slovník naučný, 1. díl A-Č, Československý Kompas, Praha, 1925, 358.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.